Home › Cardiogenic Shock › NCT05267886
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients ≥ 18 years of age admitted to an intensive care unit * SCAI class C or D cardiogenic shock Exclusion Criteria: * Unwilling or unable to obtain informed consent by the participant or substitute decision maker * Patients who are currently pregnant or breast-feeding * Patients presenting with an out-of-hospital cardiac arrest (OHCA) * Administration of milrinone or dobutamine in the 24 hours preceding anticipated randomization * Severe obstructive valvular lesions, including aortic stenosis and/or mitral stenosis * Dynamic left ventricular outflow tract obstruction
About the study
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.
What is being tested
- Dobutamine (drug)
- Milrinone (drug)
- Normal Saline (drug)
Sponsor: Ottawa Heart Institute Research Corporation · Participants: 346 · Started: Mar 5, 2022
Contact the study team
- Rebecca Mathew, MD · Phone: 613-696-7406
- Baylie Morgan, RN · Phone: 613-696-7000
Official record on ClinicalTrials.gov — NCT05267886
Locations in the U.S.
| Minnesota | Mayo Clinic, Rochester (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.